



**Michael Brines, M.D., Ph.D. Chief Scientific and Medical Officer Co-founder of Araim Pharmaceuticals, Inc. Director**

Dr. Brines received a BS with highest honors in physics and biology from the University of Notre Dame and a PhD in neurobiology and behavior from The Rockefeller University. Subsequently, he was awarded a MD from Yale University and completed a residency in Internal Medicine at Yale-New Haven Hospital. Following residency, he completed fellowship training in Clinical Investigation, as well as Endocrinology, Diabetes, and Metabolism at Yale. Dr. Brines is board certified in Internal Medicine as well as in Endocrinology, Diabetes, & Metabolism. Following his medical training, Dr. Brines remained at Yale University in the department of Internal Medicine where he served on the faculty and as Co-Director of the Yale Pituitary Center and the Molecular Core of the Yale University Diabetes and Endocrinology Research Center until he joined Araim Pharmaceuticals.

In addition to expertise in neuroendocrine and adrenal medicine, Dr. Brines has had extensive research interests primarily focused upon delineating mechanisms of nervous system injury and the development of novel approaches and therapies for neurodegenerative diseases. Over the last decade while at Araim Pharmaceuticals, he and his colleagues have identified the innate repair receptor and have developed novel compounds that activate tissue protection and repair via this receptor.

Dr. Brines has been the inventor or co-inventor on numerous U.S. patents and foreign counterparts, and is the author or co-author of over 100 scientific publications.